Gtf2h2-flox Mouse
Common Name
Gtf2h2-flox
제품 ID
S-CKO-08074
Backgroud
C57BL/6JCya
품종 계통계통 ID
CKOCMP-23894-Gtf2h2-B6J-VA
상태
이 마우스 계통을 논문에서 사용할 경우, “Gtf2h2-flox Mouse (카탈로그 번호 S-CKO-08074)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
구매 가능한 제품 종류
연령
Genotype
성별
수량
표준 제공 조건은 최소 3마리의 이형접합(heterozygous) 보균자를 보장합니다. 동형접합(homozygous) 보균자 및/또는 특정 성별에 대한 브리딩 서비스도 제공됩니다.
기본 정보
품종 계통
Gtf2h2-flox
품종 계통계통 ID
CKOCMP-23894-Gtf2h2-B6J-VA
유전자명
제품 ID
S-CKO-08074
유전자 별칭
p44, 44kDa, Btf2p44, BTF2 p44, BTF2-p44
배경
C57BL/6JCya
NCBI ID
변형 내용
Conditional knockout
염색체
Chr 13
Phenotype
Datasheet
적용 분야
--
품종 계통 설명
Ensembl 전사체 ID
ENSMUST00000066984
NCBI 전사체 ID
NM_022011
타겟 영역
Exon 6~7
유효 영역 크기
~1.0 kb
유전자 연구 개요
Gtf2h2, also known as general transcription factor II subunit H2, functions in nucleotide excision repair (NER) and basal transcription [7]. It is involved in the estrogen-dependent estrogen receptor alpha (ERα) signaling pathway, and plays a role in maintaining NER-related genomic stability and affecting PAM/NF-κB signaling pathway [7].
In hepatocellular carcinoma (HCC), overexpressing Gtf2h2 had no direct effect on endothelial cell viability, migration, or permeability, but GTF2H2-enriched exosomes from Huh7 cells could inhibit human umbilical vein endothelial cells (HUVECs) phenotypes such as proliferation and migration, suggesting potential use as a novel drug for treating HCC [1]. In lung cancer, TEP linc-GTF2H2-1 was significantly downregulated in patients, and its combination with other lncRNAs could improve the diagnostic efficiency of lung cancer [2]. In spinal muscular atrophy (SMA), GTF2H2 gene deletions were analyzed in patients, and a significant difference was found between healthy and SMA subjects. Pediatric patients with GTF2H2 deletions demonstrated higher motor functions [3,5,8,9,10]. In addition, GTF2H2 was identified as one of the genes significantly differentially expressed in the tissue of patients with neuropathic pain, suggesting it may be a potential therapeutic target [6]. The N-terminal region of the transcription factor E2F1 can recruit GTF2H2, and overexpression of GTF2H2 enhanced E2F1 activation of tumor suppressor genes and induction of cell death [4].
In conclusion, Gtf2h2 has diverse functions in different biological processes and diseases. In HCC, its exosome-derived form may have anti-angiogenesis potential; in lung cancer, it could be a biomarker; in SMA, it may be related to disease severity and motor function; in neuropathic pain, it may serve as a therapeutic target. Its interaction with E2F1 also impacts tumor suppressor gene activation. These findings from various studies help to understand the biological significance of Gtf2h2 in different disease contexts.
References：
1. Li, Zhenkun, Li, Yanmeng, Ouyang, Qin, Li, Xiaojin, Huang, Jian. 2022. Exosome-derived GTF2H2 from Huh7 cells can inhibit endothelial cell viability, migration, tube formation, and permeability. In Tissue & cell, 79, 101922. doi:10.1016/j.tice.2022.101922. https://pubmed.ncbi.nlm.nih.gov/36116407/
2. Li, Xinyi, Liu, Lele, Song, Xingguo, Xie, Li, Song, Xianrang. 2021. TEP linc-GTF2H2-1, RP3-466P17.2, and lnc-ST8SIA4-12 as novel biomarkers for lung cancer diagnosis and progression prediction. In Journal of cancer research and clinical oncology, 147, 1609-1622. doi:10.1007/s00432-020-03502-5. https://pubmed.ncbi.nlm.nih.gov/33792796/
3. Karasu, Nilgun, Acer, Hamit, Akalin, Hilal, Canpolat, Mehmet, Dundar, Munis. 2024. Molecular analysis of SMN2, NAIP, and GTF2H2 gene deletions and relationships with clinical subtypes of spinal muscular atrophy. In Journal of neurogenetics, 38, 102-111. doi:10.1080/01677063.2024.2407332. https://pubmed.ncbi.nlm.nih.gov/39321203/
4. Zhao, Lin, Nakajima, Rinka, Zhou, Yaxuan, Araki, Keigo, Ohtani, Kiyoshi. 2024. The N-Terminal Region of the Transcription Factor E2F1 Contains a Novel Transactivation Domain and Recruits General Transcription Factor GTF2H2. In Biomolecules, 14, . doi:10.3390/biom14111357. https://pubmed.ncbi.nlm.nih.gov/39595534/
5. He, Jin, Zhang, Qi-Jie, Lin, Qi-Fang, Wang, Ning, Chen, Wan-Jin. 2013. Molecular analysis of SMN1, SMN2, NAIP, GTF2H2, and H4F5 genes in 157 Chinese patients with spinal muscular atrophy. In Gene, 518, 325-9. doi:10.1016/j.gene.2012.12.109. https://pubmed.ncbi.nlm.nih.gov/23352792/
6. Hu, Ling, Yin, Wei, Ma, Yao, Zhang, Qiushi, Xu, Qingbang. 2023. Gene expression signature of human neuropathic pain identified through transcriptome analysis. In Frontiers in genetics, 14, 1127167. doi:10.3389/fgene.2023.1127167. https://pubmed.ncbi.nlm.nih.gov/36816032/
7. Li, Yanmeng, Ouyang, Qin, Chen, Zhibin, Jia, Jidong, Huang, Jian. 2025. Novel role of general transcript factor IIH subunit 2 (GTF2H2) in the development and sex disparity of hepatocellular carcinoma. In Oncogene, 44, 1323-1335. doi:10.1038/s41388-025-03301-7. https://pubmed.ncbi.nlm.nih.gov/39972070/
8. Theodorou, L, Nicolaou, P, Koutsou, P, Zamba-Papanicolaou, E, Christodoulou, K. 2015. Genetic findings of Cypriot spinal muscular atrophy patients. In Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 36, 1829-34. doi:10.1007/s10072-015-2263-5. https://pubmed.ncbi.nlm.nih.gov/26017350/
9. Zhuri, Drenushe, Gurkan, Hakan, Eker, Damla, Demir, Selma, Atli, Emine Ikbal. 2022. Investigation on the Effects of Modifying Genes on the Spinal Muscular Atrophy Phenotype. In Global medical genetics, 9, 226-236. doi:10.1055/s-0042-1751302. https://pubmed.ncbi.nlm.nih.gov/36071912/
10. Liu, Zhidai, Zhang, Penghui, He, Xiaoyan, Hong, Siqi, Zou, Lin. 2016. New multiplex real-time PCR approach to detect gene mutations for spinal muscular atrophy. In BMC neurology, 16, 141. doi:10.1186/s12883-016-0651-y. https://pubmed.ncbi.nlm.nih.gov/27534852/
품질 관리 기준
정자 검사
동결 보존 전: 정자 농도 측정 및 정자 생존율 평가.
동결 보존 후: 각 배치에서 동결 보존된 정자 바이알 1개를 선택하여 체외수정(in vitro fertilization)에 사용합니다.
Environmental Standards:
SPFAvailable Region:
GlobalSource:
Cyagen문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.